Literature DB >> 31933874

Pulmonary lymphangioleiomyomatosis: a case report.

Ling Wu1, Zhou Wang2, Yongyong Wu3, Honquan Wei1, Jun Liu1.   

Abstract

Pulmonary lymphangioleiomyomatosis is a rare disease that presents with diffuse progressive destruction of the pulmonary parenchyma. The incidence is less than 1 per million. No effective treatments are currently proposed for this disease. A 29-year-old woman who was diagnosed with pulmonary lymphangioleiomyomatosis received excisional biopsy and symptomatic supportive care. She was diagnosed with pulmonary lymphangioleiomyomatosis and was treated with anti-estrogen therapy and symptomatic supportive care. Pulmonary lymphangioleiomyomatosis is a very rare tumor that cannot be effectively cured. IJCEP
Copyright © 2019.

Entities:  

Keywords:  Pulmonary lymphangioleiomyomatosis; immunohistochemistry; pathological examination

Year:  2019        PMID: 31933874      PMCID: PMC6945093     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  10 in total

1.  Lymphangioleiomyomatosis. A series of three case reports illustrating the link with high oestrogen states.

Authors:  A M Wilson; H L Slack; S A Soosay; T Taylor; F A Carey; A Grove; P H Brown; J H Winter
Journal:  Scott Med J       Date:  2001-10       Impact factor: 0.729

2.  European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.

Authors:  S R Johnson; J F Cordier; R Lazor; V Cottin; U Costabel; S Harari; M Reynaud-Gaubert; A Boehler; M Brauner; H Popper; F Bonetti; C Kingswood
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

3.  Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax.

Authors:  A Brunelli; G Catalini; A Fianchini
Journal:  Int J Gynaecol Obstet       Date:  1996-03       Impact factor: 3.561

Review 4.  Lymphangioleiomyomatosis: new insights.

Authors:  K G Kalassian; R Doyle; P Kao; S Ruoss; T A Raffin
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

5.  Clinical analysis of patients with pulmonary lymphangioleiomyomatosis (PLAM) in mainland China.

Authors:  Ling Ye; Meiling Jin; Chunxue Bai
Journal:  Respir Med       Date:  2010-06-08       Impact factor: 3.415

6.  Lymphangioleiomyomatosis: current and future.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Haidong Huang; Antonios Sakkas; Anastasios Kallianos; Aggeliki Rapti; Eirini Sarika; Ilias Karapantzos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

7.  The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis.

Authors:  Jacques Kpodonu; Malek G Massad; Rabih A Chaer; Amitra Caines; Alexander Evans; Norman J Snow; Alexander S Geha
Journal:  J Heart Lung Transplant       Date:  2005-09       Impact factor: 10.247

8.  Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis.

Authors:  E C Harknett; W Y C Chang; S Byrnes; J Johnson; R Lazor; M M Cohen; B Gray; S Geiling; H Telford; A E Tattersfield; R B Hubbard; S R Johnson
Journal:  QJM       Date:  2011-07-15

9.  Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.

Authors:  S R Johnson; A E Tattersfield
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

10.  Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

Authors:  Xiaoxiao Gu; Jane J Yu; Didem Ilter; Nickolas Blenis; Elizabeth Petri Henske; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-27       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.